Trastuzumab deruxtecan for HER2-positive breast cancer brain metastasis: A systematic review and meta-analysis

被引：0
|
作者：
Michelon, I. F. [1 ]
Vilbert, M. Silveira [2 ]
Marinho, A. D. [3 ]
Castro, C. E. D. R. [4 ]
Dacoregio, M. I. [5 ]
Stecca, C. [6 ]
Soares, L. R. [7 ]
机构：
[1] Univ Catolica Pelotas, Med Dept, Pelotas, Brazil
[2] UHN Univ Hlth Network, Dept Clin Oncol, Princess Margaret Canc Ctr, Toronto, ON, Canada
[3] HUGG UNIRIO Hosp Univ Gaffree & Guinle, Med, Rio De Janeiro, Brazil
[4] UnB Univ Brasilia, Fac Gama FGA, Brasilia, Brazil
[5] Univ Estadual Centro Oeste, Med, Guarapuava, Brazil
[6] Ctr Oncol Parana, Dept Med, Curitiba, Brazil
[7] Univ Fed Goias, Mastol Program, Goiania, Brazil
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.591
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
414P
引用
收藏
页码：S357 / S357
页数：1
相关论文
共 50 条
  • [1] Trastuzumab Deruxtecan in HER2-positive metastatic Breast Cancer
    Lorenz, Judith
    [J]. GEBURTSHILFE UND FRAUENHEILKUNDE, 2024, 84 (08) : 670 - 670
  • [2] Trastuzumab Deruxtecan: A Review in Unresectable or Metastatic HER2-Positive Breast Cancer
    Nie, Tina
    Blair, Hannah A.
    [J]. TARGETED ONCOLOGY, 2023, 18 (03) : 463 - 470
  • [3] Trastuzumab Deruxtecan: A Review in Unresectable or Metastatic HER2-Positive Breast Cancer
    Tina Nie
    Hannah A. Blair
    [J]. Targeted Oncology, 2023, 18 : 463 - 470
  • [4] Herceptin® (trastuzumab) in HER2-positive early breast cancer: a systematic review and cumulative network meta-analysis
    Wilson, Florence R.
    Coombes, Megan E.
    Brezden-Masley, Christine
    Yurchenko, Mariya
    Wylie, Quinlan
    Douma, Reuben
    Varu, Abhishek
    Hutton, Brian
    Skidmore, Becky
    Cameron, Chris
    [J]. SYSTEMATIC REVIEWS, 2018, 7
  • [5] Trastuzumab combined to neoadjuvant chemotherapy in patients with HER2-positive breast cancer: A systematic review and meta-analysis
    Valachis, Antonis
    Mauri, Davide
    Polyzos, Nikolaos P.
    Chlouverakis, Grigoris
    Mavroudis, Dimitrios
    Georgoulias, Vassilios
    [J]. BREAST, 2011, 20 (06): : 485 - 490
  • [6] Trastuzumab uptake in HER2-positive breast cancer patients: a systematic review and meta-analysis of observational studies
    Martin, Antony P.
    Downing, Jennifer
    Cochrane, Madeleine
    Collins, Brendan
    Francis, Ben
    Haycox, Alan
    Alfirevic, Ana
    Pirmohamed, Munir
    [J]. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2018, 130 : 92 - 107
  • [7] TRASTUZUMAB UPTAKE IN HER2-POSITIVE BREAST CANCER PATIENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF OBSERVATIONAL STUDIES
    Martin, A. P.
    Downing, J.
    Collins, B.
    Cochrane, M.
    Francis, B.
    Haycox, A.
    Alfirevic, A.
    Pirmohamed, M.
    [J]. VALUE IN HEALTH, 2018, 21 : S43 - S43
  • [8] Herceptin® (trastuzumab) in HER2-positive early breast cancer: a systematic review and cumulative network meta-analysis
    Florence R. Wilson
    Megan E. Coombes
    Christine Brezden-Masley
    Mariya Yurchenko
    Quinlan Wylie
    Reuben Douma
    Abhishek Varu
    Brian Hutton
    Becky Skidmore
    Chris Cameron
    [J]. Systematic Reviews, 7
  • [9] Trastuzumab biosimilars vs trastuzumab originator in the treatment of HER2-positive breast cancer: a systematic review and network meta-analysis
    Liu, Tong
    Liu, Duo
    Jin, Yao
    Dong, Mei
    [J]. IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY, 2022, 44 (06) : 809 - 815
  • [10] Trastuzumab deruxtecan: A quantum leap in HER2-positive breast cancer
    Dhanushkodi, Manikandan
    [J]. INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY, 2019, 40 (04) : 556 - 558
12345